Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension:

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive n...